Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 9
Submit an article Journal homepage
570
Views
51
CrossRef citations to date
0
Altmetric
Review

Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis

Francesca Fantuzzi University of Verona, Department of Biomedical and Surgical Sciences, Section of Dermatology and Venereology, Piazzale A. Stefani 1, 37126 Verona, Italy +39 045 8122647; +39 045 8300521; [email protected]
,
Micol Del Giglio University of Verona, Department of Biomedical and Surgical Sciences, Section of Dermatology and Venereology, Piazzale A. Stefani 1, 37126 Verona, Italy +39 045 8122647; +39 045 8300521; [email protected]
,
Paolo Gisondi University of Verona, Department of Biomedical and Surgical Sciences, Section of Dermatology and Venereology, Piazzale A. Stefani 1, 37126 Verona, Italy +39 045 8122647; +39 045 8300521; [email protected]
&
Giampiero Girolomoni University of Verona, Department of Biomedical and Surgical Sciences, Section of Dermatology and Venereology, Piazzale A. Stefani 1, 37126 Verona, Italy +39 045 8122647; +39 045 8300521; [email protected]
Pages 1085-1096 | Published online: 12 Aug 2008

Bibliography

  • Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
  • Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis-recent developments. Immunol Lett 2007;114:59-65
  • Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41
  • Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73
  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
  • Ottaviani C, Nasorri F, Bedini C, et al. CD56brightCD16- NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006;36:118-28
  • Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. J Autoimmun 2005;25:69-73
  • Mee JB, Johnson CM, Morar N, et al. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 2007;171:32-42
  • Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defence and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40
  • Conrad C, Boyman O, Tonel G, et al. α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007;13:836-42
  • Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev Dermatol 2007;2:69-78
  • Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50
  • Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α. J Immunol 1999;162:494-502
  • Albanesi C, Scarponi C, Federici M, et al. Interleukin 17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin 4-induced activation of human keratinocytes. J Invest Dermatol 2000;115:81-7
  • Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607
  • Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defence, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-23
  • Li J, Li D, Tan Z. The expression of IL-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci 2004;24:294-6
  • Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
  • Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30
  • Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
  • Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
  • Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7
  • Albanesi C, De Pità O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007;25:581-8
  • Diluvio L, Vollmer S, Besgen P, et al. Identical TCR β-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006;176:7104-11
  • Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-73
  • Giustizieri ML, Mascia F, Frezzolini A, et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-7
  • Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006;116:2094-104
  • Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9
  • Albanesi C, Scarponi C, Pallotta S. Role of the chemerin-ChemR23 axis in the recruitment of plasmacytoid dendritic cells in psoriatic skin. J Exp Med 2008(In Press)
  • Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005;102:19057-62
  • Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-9
  • Gisondi P, Gubinelli E, Cocuroccia B, Girolomoni G. Targeting tumor necrosis factor-α in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:175-83
  • Lebre MC, Antons JC, Kalinski P, et al. Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor α type I interferons, and interleukin-18. J Invest Dermatol 2003;120:990-7
  • Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214:149-60
  • MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002;14:477-92
  • Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993;143:1724-30
  • Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. J Biol Chem 1993;268:18542-8
  • Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signalling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004;15:353-66
  • Friedmann E, Hauben E, Maylandt K, et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNF-α in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006;8:843-8
  • Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys 2007;26:159-67
  • Legler DF, Micheau O, Doucey MA, et al. Recruitment of TNF receptor 1 to lipid rafts is essential for TNF-α- mediated NF-κB activation. Immunity 2003;18:655-64
  • Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-α-induced skin inflammation. Eur J Immunol 1997;27:1713-8
  • Pasparakis M, Courtois G, Hafner M, et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002;417:861-6
  • Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003;171:2262-9
  • Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I. Langerhans cell migration. Clin Exp Dermatol 2000;25:413-8
  • Ritter U, Meissner A, Ott J, Körner HJ. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-α reveals an essential role for TNF. Leukoc Biol 2003;74:216-22
  • Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173-81
  • Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12
  • Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ. Role of NF-κB activity in apoptotic response of keratinocytes mediated by interferon-γ, tumor necrosis factor-α? and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol 2001;117:898-907
  • O'Kane M, Markham T, McEvoy AN, et al. Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-αinhibition. J Invest Dermatol 2008;128:300-10
  • Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008;128:1365-74
  • Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13
  • Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31
  • Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumtol 2005;1:47-53
  • Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-51
  • O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004;63:354-9
  • Mangashetti LS, Khapli SM, Wani MR. IL-4 inhibits bone resorbing activity of mature osteoclasts by affecting NF-kappa and calcium signaling. J Immunol 2005;175:917-25
  • Kotake SL, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes. Arthritis Rheum 2001;44:1003-12
  • Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69
  • Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
  • Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomised, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42
  • Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind randomized controlled trial and open label extension study. J Am Acad Dermatol 2006;55:598-606
  • Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
  • Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
  • Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31-44
  • Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-31
  • Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51
  • Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35
  • Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis. Br J Dermatol 2008;158:558-66
  • Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomised, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
  • De Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006;45:321-4
  • Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
  • Frankel EH, Strober BE, Crowley JJ, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007;79:322-6
  • Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88
  • Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol 2007;34:1040-50
  • Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505
  • Van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707
  • Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64:78-82
  • Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
  • Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22
  • Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
  • Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9
  • Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95
  • Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
  • Dalle Vedove C, Schena D, Girolomoni G. Drug-induced lupus erithematosus: a review of literature. Arch Dermatol Res 2008; In press
  • Gisondi P, Cotena C, Tessari G, Girolomoni G. Effects of anti-TNF-α therapy on body weight of patients with psoriasis: a retrospective control study. J Eur Acad Dermatol Venereol 2008;22:341-4
  • Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8
  • Dixon WG, Watson KD, Lunt M, Hyrich KL. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12
  • Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5
  • Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26
  • Kohno T, Tam LTT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Invest Dermatol Symp Proc 2007;12:5-8
  • Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 2003;12:190-4
  • Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-α as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs 2002;3:1590-5
  • Goedkoop AY, Kraan MC, Teunissen MB, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:326-34
  • Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and downregulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006;54:1003-12
  • Bedini C, Nasorri F, Girolomoni G, et al. Antitumor necrosis factor-α chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007;157:249-58
  • Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9
  • Tan JK, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Invest Dermatol Symp Proc 2007;12:38-45
  • Gordon KB, Bonish BK, Patel T, et al. The tumor necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005;153:945-53
  • Heider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFN-γ antibodies: TNF regulates IFN-γ production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 2008;128:655-66
  • Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007;204:33-9
  • Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007;12:9-15
  • Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;13:3183-94
  • Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor specific bioassays. Gastroenterology 2006;130:A697
  • Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004;15:353-66
  • Friedmann E, Hauben E, Maylandt K, et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNF-α? in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006;8:843-8
  • Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
  • Anandarajah AP, Schwarz EM, Totterman S, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:296-301
  • Punzi L, Podswiadek M, Sfriso P, et al. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 2007;6:524-8
  • Fiocco U, Ferro F,Vezzu M, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005;64:899-905
  • Banno T, Gazel A, Blumenberg M. Effects of TNFα in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004;279:32633-42
  • Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158:1345-9
  • He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-α. Science 2005;310:1022-5
  • Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumour necrosis factor-α-converting enzyme in psoriasis. Br J Dermatol 2005;152:915-9
  • Moriyama H, Tsukida T, Inoue Y, et al. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem 2004;47:1930-8
  • Qian M, Bai SA, Brogdon B, et al. Pharmacokinetics and pharmacodynamics of DPC 333. ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor α-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metab Dispos 2007;35:1916-25
  • Chun K, Park SK, Kim HM, et al. Chromen-based TNF-α converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem 2008;16:530-5
  • Holtmann MH, Neurath MF. Differential TNF-signalling in chronic inflammatory disorders. Curr Mol Med 2004;4:439-44
  • Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-75
  • Papp KA, Tyring S, Lahfa M, et al.; Etanercept Psoriasis Study Group. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
  • Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
  • Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.